Who are Safinamide (as add-on therapy)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Rasagiline mesylate with Requip, Safinamide Methanesulfonate, rasagiline (Pharmacodynamics), Rasagiline mesylate with Levodopa, MMI, Rasagiline mesylate plus Mirapex.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/safinamide-as-add-on-therapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Safinamide (as add-on therapy) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safinamide (as add-on therapy) (Safinamide (as add-on therapy)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: MAO-B inhibitor. Area: Neurology.

phase 3 MAO-B inhibitor MAO-B Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Safinamide (as add-on therapy) (Safinamide (as add-on therapy)) — Newron Pharmaceuticals SPA. Safinamide is a monoamine oxidase B (MAO-B) inhibitor that also has a weak inhibitory effect on monoamine oxidase A (MAO-A).

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Safinamide (as add-on therapy) TARGET	Safinamide (as add-on therapy)	Newron Pharmaceuticals SPA	phase 3	MAO-B inhibitor	MAO-B
Rasagiline mesylate with Requip	Rasagiline mesylate with Requip	Teva Neuroscience, Inc.	marketed	MAO-B inhibitor combined with dopamine receptor agonist	MAO-B and dopamine D2/D3 receptors
Safinamide Methanesulfonate	Safinamide Methanesulfonate	Zambon SpA	marketed	Monoamine oxidase B (MAO-B) inhibitor	MAO-B (Monoamine oxidase B)
rasagiline (Pharmacodynamics)	rasagiline (Pharmacodynamics)	University of Maryland, Baltimore	marketed	Monoamine oxidase B (MAO-B) inhibitor	MAO-B (Monoamine oxidase type B)
Rasagiline mesylate with Levodopa	Rasagiline mesylate with Levodopa	Teva Neuroscience, Inc.	marketed	MAO-B inhibitor combined with dopamine precursor	Monoamine oxidase B (MAO-B); Dopamine pathway
MMI	MMI	Xiao-Ming Mao	marketed	MAO-B inhibitor	MAO-B
Rasagiline mesylate plus Mirapex	Rasagiline mesylate plus Mirapex	Teva Neuroscience, Inc.	marketed	MAO-B inhibitor plus dopamine agonist combination	Monoamine oxidase B and dopamine D2/D3 receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (MAO-B inhibitor class)

Newron Pharmaceuticals SPA · 1 drug in this class
Xiao-Ming Mao · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Safinamide (as add-on therapy) — Competitive Intelligence Brief. https://druglandscape.com/ci/safinamide-as-add-on-therapy. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab